All In MedTech

FDA Clearance Tracker · P140031-S202

Edwards SAPIEN 3 Ultra™ RESILIA Transcatheter Heart Valve

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 22, 2026

Approved

Time to decision

188 days

Received Apr 17, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P140031-S202
Device name
Edwards SAPIEN 3 Ultra™ RESILIA Transcatheter Heart Valve
Applicant location
Irvine, CA
Received
Apr 17, 2026
Decided
Oct 22, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P140031

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

approval for a manufacturing site located at CENTERPIECE (Bulevar La Encantada Industrial, Parque Industrial El Floride, Seccion La Encantada # 11530, Tijuana Baja California, Mexico 22250) for terminal ethylene oxide sterilization.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.